# ImCheck Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/imcheck-therapeutics

- Industry: Biotechnology
- Headquarters: Marseille, France
- Website: www.imchecktherapeutics.com
- Total disclosed funding: $131M
- Latest round: Series C (Sep 22, 2022)
- Investors on record: 15

## About

Based in France, ImCheck Therapeutics SAS focuses on developing innovative immunotherapeutic antibodies that modulate the immune system, addressing complex medical conditions such as cancer and autoimmune disorders.ImCheck Therapeutics SAS, established in 2015 in Marseille, France, specializes in the development of immunotherapeutic products. Pierre d'Epenoux serving as the CEO. In October 2025, Ipsen Group agreed to fully acquire ImCheck Therapeutics SAS from Kinled Holding, Boehringer Ingelheim Venture, Eurazeo, Kurma Partners, EQT Life Sciences, Gimv, Bpifrance, Agent Capital, Alexandria Venture Investments, Bpifrance Investissement, Pfizer Venture Investments, Wellington Partners, Pureos Bioventures, Earlybird Venture Capital, Invus [DUP], The Leukemia & Lymphoma Society for an upfront payment of EUR 350 million. The deal is subject to customary closing condition and is expected to be completed on the end of first quarter of 2026. The transaction valued the company at over EUR 350 million.ImCheck Therapeutics specializes in the development of innovative immunotherapeutic antibodies aimed at modulating the immune system through their proprietary knowledge of butyrophilin (BTN) and BTN-like (BTNL) checkpoint molecules. Their core offerings include ICT01 and ICT41, designed to address the complexities of cancer, infectious diseases, and autoimmune disorders, leveraging a novel approach to harness gamma-delta T cells.ImCheck Therapeutics generates revenue through strategic partnerships and collaborations centered on their flagship products, notably ICT01, focusing on acute myeloid leukemia (AML). Revenue is derived from milestone payments and royalties based on product candidates' success, structured through agreements that outline specific deliverables and performance metrics. The company aims to maximize revenue through continued research advancements and commercialization of its proprietary therapy products.In October 2025, Ipsen Group agreed to fully acquire ImCheck Therapeutics SAS. The company plans to advance its oncology pipeline by integrating ImCheck’s ICT01 antibody program for acute myeloid leukemia into late-stage clinical development.

## Funding rounds

- Series C, Sep 22, 2022, $65M — Wellington Partners, Andera Partners, EQT Life Sciences, Eurazeo, Gimv, Alexandria Venture Investments, Earlybird, Invus [DUP], Boehringer Ingelheim Venture, Kurma Partners, Pfizer Venture Investments, The Leukemia & Lymphoma Society, Bpifrance Investissement, Agent Capital, Pureos Bioventures
- Series B, Aug 5, 2021, $19M — Wellington Partners, EQT Life Sciences, Eurazeo, Gimv, Alexandria Venture Investments, Boehringer Ingelheim Venture, Kurma Partners, Pfizer Venture Investments, Bpifrance Investissement, Agent Capital, Pureos Bioventures
- Series B, Aug 24, 2020, $3M — Pureos Bioventures
- Series B, Nov 12, 2019, $22M — Wellington Partners, EQT Life Sciences, Eurazeo, Gimv, Alexandria Venture Investments, Boehringer Ingelheim Venture, Kurma Partners, Pfizer Venture Investments, Bpifrance Investissement, Agent Capital
- Series A, Jun 13, 2018, $14M — EQT Life Sciences, Gimv, Boehringer Ingelheim Venture, Kurma Partners
- Series A, Jun 20, 2017, $5.6M — EQT Life Sciences, Eurazeo, Gimv
- Series A, Nov 3, 2016, $2.6M — Eurazeo, Boehringer Ingelheim Venture, Kurma Partners

## Investors

- Eurazeo (https://capitalatlas.ai/funds/eurazeo) — Series A, Series B, Series C
- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Series A, Series B, Series C
- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Series A, Series B, Series C
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A, Series B, Series C
- Gimv (https://capitalatlas.ai/funds/gimv) — Series A, Series B, Series C
- Wellington Partners (https://capitalatlas.ai/funds/wellington-partners) — Series B, Series C
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B, Series C
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series B, Series C
- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Series B, Series C
- Agent Capital (https://capitalatlas.ai/funds/agent-capital) — Series B, Series C
- Pureos Bioventures (https://capitalatlas.ai/funds/pureos-bioventures) — Series B, Series C
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series C
- Earlybird (https://capitalatlas.ai/funds/earlybird) — Series C
- Invus [DUP] — Series C
- The Leukemia & Lymphoma Society — Series C